Clinical Trial Update: Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating camrelizumab with chemotherapy and ivaramacitinib as neoadjuvant therapy for resectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Ivarmacitinib

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING